Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Sunshine Biopharma Inc./ PRE 14C

SEC Filing · PRE 14C

Sunshine Biopharma Inc.

SBFMNASDAQEQUITYCurrent

SEC Filing

Filed Oct 14, 2026Accepted Oct 14, 2026, 5:21 PM EDTCIK 1402328Accession 0001683168-26-007847
View company →Permanent SEC source ↗
Share

Company context

We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc., a Canadian corporation, through which we currently have 60 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc., a Canadian corporation through which we develop and sell OTC supplements.

Current securities

SBFMNASDAQ · EQUITY · CurrentSBFMWNASDAQ · WARRANT · Current
Historical securities (6)
SBFMOTC · EQUITY · Historical · closed Feb 1, 2019SBFMOTC · EQUITY · Historical · closed Apr 6, 2020SBFMOTC · EQUITY · Historical · closed Feb 9, 2022SBFMDOTC · EQUITY · Historical · closed Mar 1, 2019SBFMDOTC · EQUITY · Historical · closed May 1, 2020SBFMDOTC · EQUITY · Historical · closed Feb 15, 2022

Recent company filings

  1. Submission of Matters to a Vote of Security HoldersOct 14, 2026
  2. Entry into a Material Definitive Agreement · Other EventsOct 9, 2026
  3. 424B4 filingOct 9, 2026
  4. EFFECT filingOct 7, 2026
  5. S-1 filingOct 2, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.